L1CAM High Expression Associates with Poor Prognosis in Glioma but Does Not Correlate with C11orf95-RELA Fusion

Abstract EN

The latest WHO guideline of CNS tumor defined a RELA fusion-positive ependymoma type with extremely poor prognosis, and the expression of L1CAM was correlated well with the presence of RELA fusion.

However, the L1CAM protein expression in large sample gliomas other than ependymoma, its relationship with the RELA gene and its prognostic significance remained unknown.

We examined the expression of L1CAM in 565 glioma cases (WHO grade I-IV).

The L1CAM IHC-positive cases were selected to test RELA fusion with FISH break-apart probes.

L1CAM was positive in 109 cases (19.29%) of all 565 glioma cases, with 18.27% in low-grade gliomas and 19.84% in high-grade gliomas, respectively.

Unlike ependymoma, L1CAM protein expression was not correlated with the C11orf95-RELA fusion gene in other gliomas, but it had correction with the patient age (older than 45-year-old, p=0.006), ATRX mutation (p=0.003) and Ki67 (p=0.007).

High expression of L1CAM was an independent prognostic factor in our cohort.

Further analysis demonstrated that L1CAM strong positive expression was significantly associated with poor prognosis in gliomas, both in our cohort (p<0.001) and TCGA (p<0.009) dataset.

Although uncorrelated with C11orf95-RELA fusion, L1CAM was a significant poor prognostic marker in glioma patients.

More aggressive treatment should be taken for these patients and L1CAM might be a promising therapeutic target in glioma.